In models of hind-limb ischemia and progressive coronary artery occlusion, angiogenic growth factor proteins and genes expressing growth factors have been shown to induce the development of collateral vessels and remodeling of existing collaterals. The therapeutic potential of growth factors in the setting of acute myocardial infarction may be related to non-angiogenic properties of growth factors as well, and is the focus of this review.
Introduction
An interesting hypothesis is that the development of new vessels (angiogenesis) or the remodeling of preexisting Acute myocardial infarction (AMI) is a leading cause of collaterals may form natural bypasses that could compendeath and disability in the Western World. In the United sate for the occlusion of an epicardial coronary artery, States, 1.5 million people are hospitalized annually with improving the outcome after AMI. AMI [1] , and AMI is responsible for 25% of all deaths [1] .
Several growth factors such as fibroblast growth factors Moreover, a substantial number of AMI survivors are (FGFs) [10, 11] . Vascular Endothelial Growth Factor significantly disabled; thus, the social costs of this disease (VEGF) [12, 13] . and Insulin Growth Factors (IGFs) are enormous. [14, 15] have angiogenic properties. During recent years, a In the last four decades, substantial advances have been number of experimental studies have suggested that treatachieved in the treatment of AMI. Treatment of potentially ment with angiogenic growth factors can promote the fatal arrhythmias in Coronary Care Units [2] , infarct size development of collaterals to ischemic tissue in models of reduction strategies through the introduction of nitrates [3] , progressive coronary occlusion [16] [17] [18] [19] , and AMI [20-beta-blockers [4] , and surgery [5] , and most importantly, 22]. thrombolytic agents [6] and direct PTCA [7] have imAngiogenic growth factors have been shown to reduce portantly decreased mortality from AMI. These developinfarct size and improve left ventricular ejection fraction in ments have reduced the in-hospital mortality to as low as animal models of AMI [20, 23] . The reduction in infarct 3% in selected populations of patients with AMI treated by size was associated with increased vascularity in one direct PTCA [7] . Despite the impact of these developstudy, suggesting that an angiogenic mechanism was ments, however, heart failure remains the leading cause of operative in reducing infarct size [20] . Nevertheless, it is in-hospital morbidity and mortality in AMI patients [8] .
counterintuitive to suggest that the development of new Thus, adjunctive therapies for the limitation of infarct size blood vessels could account for a reduction in infarct size, could serve to limit heart failure and advance the treatment given the extended time-frame required for vascular of AMI [9] . growth (days), compared to the limited window of opportunity for myocardial salvage (hours). In addition to their effects on angiogenesis [24] and wound healing [25, 26] , prognosis. Third, healing of the necrotic area may not be growth factors have other properties that may have imadequate if the fibroblasts do not receive adequate metaportant effects in the setting of AMI. Some growth factors bolic support. If the healing process is improved, a have been shown to be NO-dependent vasodilators [27, 28] , reduction in left ventricular remodeling, aneurysm formaand some have been reported to have direct neuroprotection and rupture can be expected. These changes may lead tive [29] and myoprotective effects [30] . Thus, these to benefit in short and long-term prognosis, as well as growth factors could importantly affect the evolution, functional class. healing and remodeling of AMI through their effects on
In patients with an AMI, it has been shown that the systemic hemodynamics and loading conditions, carextent of preexisting coronary collaterals influences infarct diomyocyte protection, angiogenesis, collateral developsize, the amount of viable myocardium, aneurysm formament, and / or wound healing.
tion, and prognosis [41] [42] [43] [44] . In patients after AMI, it has Although there are numerous studies of the effects of been demonstrated angiographically that collateral degrowth factors in chronic myocardial and limb ischemia velopment occurs mainly in the area of the necrotic tissue [31] [32] [33] , the potential role of growth factors in AMI has [45, 46] . Moreover, the preservation of LV volumes and received less attention, and is the subject of this review.
function after AMI are related to the residual flow obtained by reperfusion or by collateral vessels [47] . In the context of thrombolysis shortly after AMI, the benefits of collateral 2. Collateral vessels in acute myocardial infarction vessels in the salvage of myocardium is well documented [48] [49] [50] [51] . When thrombolysis is not successful, a lower The de novo formation of new vessels in the adult CPK release and a subsequent improvement in LV function organism (angiogenesis), as well as the remodeling of can be expected if there is a good collateral network to the innate collateral vessels (collateral remodeling) are proischemic region [48] [49] [50] . cesses that require some time to accomplish. Experiments Despite its well known angiogenic properties [12, 13] , in animals suggest that both the enlargement of preexisting and the demonstration of an overexpression of VEGF collaterals and neovascularization require approximately protein and its receptor after AMI [52, 53] , there are no 24 h for the first cellular mitosis [34] , and about 3 days for published studies on the use of VEGF as a potential the completion of a functionally relevant collateral circulatherapeutic agent in the context of AMI. The growth tion [35] . This is confirmed by the finding that collateral factors most intensively studied in AMI are the FGFs and flow appears to increase rapidly in the following days after IGFs. coronary occlusion in the dog. Four days after occlusion, During recent years, a number of experimental studies endocardial and epicardial flow have been shown to have suggested that treatment with angiogenic growth increase to 50% and 75% of their normal values, respecfactors can promote the development of collaterals to tively [36] . Ten days after coronary occlusion resting flow ischemic tissue in models of progressive coronary occluto the myocardium beyond the coronary occlusion is sion [16] [17] [18] [19] , and AMI [20] [21] [22] . normal [37] .
In humans, initial sprouts are seen 3 days after AMI, shortly after macrophage invasion and before fibroblast 3. Fibroblast growth factors proliferation and collagen deposition [38] .
Based on this information, therefore, it is difficult to 3.1. Molecular characterization conceive how either angiogenesis or collateral remodeling could play a role in infarct size reduction, given that the The FGF family of growth factors is comprised of at myocyte's window of viability is limited to a few hours least eighteen distinct, but structurally related, growth [39] .
factors. All members contain a common domain which is From a theoretical point of view, however, vascular responsible for most of their structural homology. FGF-1 development within the myocardial risk region (formation and FGF-2 are the most widely studied members of the of new vessels and / or the remodeling of innate collaterals) FGF family. may be beneficial for several reasons. First, when abundant collateral vessels are present within the risk region imme-3.2. Acidic fibroblast growth factor (FGF-1) diately after the total occlusion of a epicardial vessel, a substantial reduction or even a prevention of the myocar-FGF-1, also called acidic FGF, is a 140 amino acid dial necrosis can be observed [40] . Second, the developpeptide [54] . The three-dimensional structure of FGF-1 has ment of collateral vessels at the border zone can improve recently been shown [55] . Slightly shorter and longer local perfusion and therefore, enhance the function of the forms of FGF-1 have also been identified [54] . FGF-1 gene ischemic but otherwise viable myocardium in the penumhas been cloned and expressed [56] . FGF-1 and FGF-2 bra of the necrotic area. This may improve left ventricular have a 55% amino acid sequence homology. This suggest function and remodeling, both major determinants of that they both derived from a common ancestral gene [57] .
However, FGF-1 and FGF-2 are formed from two different vasodilator [27] , and has been reported to have direct genes in two different chromosomes, which can be exneuroprotective [29] and myoprotective [30] properties. plained by gene duplicating and evolutionary divergence [57] .
Insulin growth factors 3.3. Basic fibroblast growth factor (FGF-2)

Characteristics
The peptide of FGF-2 (basic fibroblast growth factor) has been purified and sequenced, and its gene been cloned Insulin growth factors (IGFs) I and II, also known as and expressed [58] . Southern blot analysis demonstrates somatomedins [68] , were shown to be survival factors to that FGF-2 is encoded by a single gene [59] . The singlemotor neurons [69] . IGF-I gene expression in mammals copy gene for human FGF-2 (FGFB) has been localized on typically results in multiple mRNA species ranging in size chromosome 4 [60] . The three-dimensional structure of between 0.7 and 7.6 kb [70]. IGF-I and II are single-chain FGF-2 has been elucidated [55] .
polypeptides usually of 7. [62] .
as potent as FGF-2 in promoting rabbit corneal angioMultiple molecular forms of FGF-2 have been reported genesis [73] . Moreover, IGF-I seems to participate in the [63] . These proteins are synthesized from one mRNA healing process [74] . species, and some initiate translation at non-AUG codons [63] . Human FGF-2 is expressed in four forms: an 18 kDa (155-amino acid) form generated by initiation at the AUG 4.2. FGFs and acute myocardial infarction codon, and 22, 22.5 and 24 kDa forms (196, 201 , and 210-amino acids) arising from the CUG codons located Franco et al. [23] was the first to report on the effects of upstream of the conventional AUG start site [63] . The high FGF-2 in AMI. In his cat model, AMI was induced by molecular forms of FGF-2 contain the complete amino occlusion of the left anterior descending artery (LAD). acid sequence of the 18 kDa form in addition to NH -FGF-2 (25 mg) was suspended in Sephadex beads and 2 terminal extensions of varying lengths. injected directly into the ischemic myocardium, 2 min after The N-extension of FGF-2 confers a nuclear localization coronary occlusion. The authors claimed that infarct size signal [64] , and increases FGF-2 nuclear localization was reduced with this treatment, and speculated that this which usually is associated with cell proliferation [65] .
effect was mediated by myoprotective effects of FGF-2. The FGF-2 molecular heterogeneity is further complicated Using a canine proximal LAD ameroid model, Banai et by the fact that FGF-2 isolated from tissues is sometimes al. [18] reported a 44% incidence of AMI. Three weeks truncated by enzymatic degradation. For example, FGF-2 after ameroid placement, a sponge saturated with FGF-1 has been found as a 131-amino acid form in the ovary,
(1-800 mg) was interposed between a vascular pedicle and kidney and adrenal tissue, as a 146-amino acid protein in the epicardium in the LAD territory. They reported that the brain and pituitary, and as a 157-amino acid protein in myocardial perfusion was not significantly increased in the placenta [66, 67] . treated dogs; however, striking vascular smooth muscle Basic FGF has numerous properties that could come into cell hyperplasia was evident in arterioles and small arplay in the setting of AMI. In addition to its effects on teries, exclusively in areas of subendocardial infarction. In angiogenesis [24] and wound healing [25] , basic FGF has some areas smooth muscle cells hyperplasia was extreme, been shown to be a moderately potent NO-dependent causing occlusion of the vessels. This result probably was a consequence of the high local level of the growth factor reducing the risk region in FGF-2-treated animals. Risk achieved in the myocardial tissue.
region was not reported in this study. Yanagisawa-Miwa et al. [20] administered intracoronary Miyataka et al. [79] administered 300 mg of FGF-2 FGF-2 (10 mg) into the left circumflex coronary artery directly into the myocardium supplied by the LAD just (LCx), 30 min and 6 h after LAD occlusion in dogs. The before the coronary occlusion in dogs. Myocardial perfu-LAD occlusion was induced by the delivery of an artificial sion was reported to be enhanced 4 weeks after occlusion thrombus to a segment of the coronary artery previously in the subendocardial, midmyocardial, and subepicardial made stenotic by laser thermal injury. One week later, regions in FGF-2-treated animals. However, this difference there was a reduction in infarct size (5% vs. 20%), a better was only seen when the data was presented as ischemic LV ejection fraction (94% vs. 45% from baseline), and an zone / normal zone ratio. In absolute terms, there were no increase in the number of capillaries and arterioles in the difference. There was less necrotic myocardium in the FGF-2-treated animals, without any significant deleterious ischemic region as well as less fibrosis in the FGF-2-hemodynamic effects. These authors hypothesized that the treated animals [79] . The authors reported 50% mortality angiogenic response was the cause of myocardial salvage.
in both groups. This may have induced a selection bias However, this is unlikely, given that the first division of towards dogs with higher values of myocardial perfusion. endothelial cells requires nearly 24 h after the onset of In this study, both necrosis and fibrosis were reported as ischemia [75,76] and 2-3 days are required after FGF-2 subjective scores. administration for the formation of new capillaries [77, 78] .
In a rabbit model, Hasegawa et al. injected 100 mg of In dogs, it is known that the necrotic process is almost FGF-2 into the myocardium supplied by the LAD, prior to completely established after 4 h of ischemia [39] . Thereacute occlusion [80] . There was subjectively less fibrosis fore, it is highly unlikely that the angiogenic effect can and more viable myocardium in the border zone in FGFhave had any significant role in the reduction of necrosis. treated animals; however, microsphere perfusion within the Yanagisawa-Miwa et al. [20] did not report the spontainfarcted area was not enhanced. Interestingly, increased neous rate of LAD recanalization in the first hours after perfusion was observed in the noninfarcted area of FGF-AMI. treated rabbits. The reasons for this are unclear.
In another study, Battler et al. [21] induced focal MI in
Watanabe et al. [81] induced an AMI in pigs by placing pigs by embolizing sustained-release beads containing an embolization coil in the distal LAD. Four to five weeks FGF-2 (0,12 mg / kg) into the distal LAD. Thus, the growth later each animal was injected in eight nearby myocardial factor was immediately available at sites of focal infarcpoints with FGF-2 alone (10 mg), or FGF-2 combined with tion. Increased vascular number was observed in FGF-2-heparan sulfate, heparin, or beads. From these eight treated animals at day 14. There was no evidence of injection points four were placed in the normal myocarimprovement in LV function as evaluated by echocardiogdium and four at the border zone. FGF-2 angiogenic raphy. The sizes of the risk regions and zones of necrosis potential was evaluated 4-5 weeks after injection. An were not reported, but were probably small given that no increased number of vessels was detected, particularly deaths or arrhythmias occurred in either group, and no after FGF-2 plus heparin treatment. These data are difficult significant changes in blood pressure were observed in the to interpret because the different treatment regimens were control group after the induction of AMI.
tested in the same animal in adjacent areas of the myocarUchida et al. [22] induced AMI in dogs by embolizing dium. Some of these agents may have had interfering 0.1 ml of inorganic mercury into the LAD. The dogs were actions in adjacent regions. randomized into four experimental groups: saline; heparin Scheinowitz et al.
[82] gave intraperitoneal FGF-2 in (3 mg), FGF-2 (30 mg) or FGF-2 (30 mg)1heparin (3 rats, starting immediately after AMI, continuing for a mg). These drugs were administered into the pericardial duration of one week. Six weeks after AMI, LV cavity cavity through the right atrium using a thin needle-tipped diameter was smaller and wall thickness was larger in catheter. In this study they did not report the time of FGF-2-treated animals, outside the necrotic zone [82] . In a administration of the drugs after coronary occlusion. The similar study, the same group reported that intraperitoneal authors considered this procedure to be relative safe, FGF-2 administration was not associated with changes in because they did not observe any tamponade, even in dogs left ventricular geometry [83] . that received heparin. One month later, they observed a These studies are summarized in Table 1 . significant reduction in myocardial necrosis and an improvement in LV function in FGF-2-treated dogs. This 4.3. FGFs and reperfusion benefit was even greater in dogs treated with FGF-2 plus heparin. These changes were correlated with changes in
Using an in vitro model Padua et al.
[84] demonstrated vascular number. No deaths were reported. The vasodilatthat FGF-2-perfused hearts (5-20 mg / heart) exhibited ory properties [27] of FGF-2 may have had a confounding increased resistance to ischemia-reperfusion injury. FGFeffects on the results. Vasodilatation could have allowed treated hearts also showed improved functional recovery the mercury to migrate distally in the coronary circulation, after ischemia-reperfusion injury. This study was the first to demonstrate a cardioprotective effect of FGF-2, similar divided into nine experimental groups. These authors to that previously reported with neuronal cells [85] .
suggested that local intramyocardial infusion of FGF-1 Using a canine model in which 4-h mid-LAD occlusion (0,5 mg / ml, 20 ml / min) and / or FGF-2 (2 mg / ml), 60 min was followed by reperfusion, Horrigan et al. [86] demonbefore the occlusion of the LAD was associated with a strated reduction in infarct size in FGF-2-treated animals protection similar to that obtained by ischemic precondi-(10 mg infused intracoronary twice, 109 after occlusion, tioning. This effect was receptor-mediated and also reand just before reperfusion). FGF-2 treatment was not quired the mitogenic portion of the FGF molecule [89] . associated with beneficial effects on ejection fraction, Moreover, FGF-1 and FGF-2 administration did not prehemodynamic improvement, or evidence of neovascularivent cell necrosis, but only delayed the process doubling zation. Several unexpected findings were reported in this the time necessary for complete infarction. study. The necrotic area (expressed as a percentage of the These studies are summarized in Table 2 . risk region) in the control group was particularly low (28%) 4 h after occlusion. (Usually between 75-90% of 4.4. IGFs and acute myocardial infarction the myocardial tissue inside the risk region is necrotic 3 h after coronary occlusion [39] ). No coronary vasodilatory
In patients with AMI, increased IGF-1 levels have been effects were found after the intracoronary administration of associated with improved left ventricular remodeling and up to 100 mg of FGF-2. This is in contradistinction to function [90] . Based on experimental animal studies, another report that showed that FGF-2 is a coronary however, the role of IGF-1 in myocardial remodeling is vasodilator in dogs [24] . less clear. Using a transgenic mouse model overexpressing In addition to necrosis, a number of myocytes undergo IGF-1B in cardiac myocytes, Li et al. [91] demonstrated apoptosis during ischemia-reperfusion injury. In post-morthat constitutive expression of IGF-1 prevented necrosis of tem studies in humans that died shortly after AMI, viable myocardium after AMI, reducing ventricular dilaapoptotic myocytes were frequently found after successful tion and improving myocardial loading and hypertrophy. thrombolysis [87] . Cuevas et al. [88] suggested in rats (20 In a study in which IGF-1 protein was administered to rats min of ischemia124 h of reperfusion) that the apoptotic with AMI, there was no apparent effect on left ventricular process triggered by ischemia-reperfusion injury is reduced geometry [83] . after FGF-1 administration (both native FGF-1 and a
There are also suggestions that IGF-2 may improve non-mitogenic isoform), shortly after the induction of the regional cardiac function by inducing regional myocardial ischemia [88] .
hypertrophy in peri-infarct areas [92] . In a recent study, Htun et al. [89] studied the effects of FGF-1 and FGF-2 severely dysfunctional myocardium (after MI) was found in pigs subjected to LAD occlusion for 45, 60 or 90 min, to undergo additional hypertrophy and functional improvefollowed by 120 min of reperfusion. These animals were ment in response to IGF-1 [93] . [20, 22, 23, 86, 89, 95] may also be a source of error. Alupregulated by ischemia-reperfusion and also by surgical though less expensive and labor intensive, positive staining stress. IGFBP-5 appears 30 min after IGF [94] , a period of with tetrazolium is not synonymous of myocyte viability time coincident with the ''window'' in which the myocar- [97] . Moreover, macroscopic analysis is not able to dium is protected by preconditioning.
identify the complex microscopic interdigitations between Vogt et al. [95] used a pig coronary occlusion model infarcted and normal myocardium [97] . followed by 120 min of reperfusion. Using this model, the In some of the reviewed studies, the number of myocarintramyocardial injection of IGF-II (0,25 mg / ml, over 60 dial vessels was assessed in the absence of perfusionmin) delayed the onset of MI. This effect is similar to that fixation [20] [21] [22] . Under these circumstances, many vessels of insulin administration, which results from insulin remay be missed. ceptor activation and is prevented by IGFBP-5 and lavenIn one study [21] , heparin was administered with the dustin A, a tyrosine kinase protein inhibitor.
growth factor. Heparin is a known angiogenic factor [98-In a rat model of myocardial ischemia (20 min) and 100], and may have influenced the final result in this reperfusion (24 h), Buerke et al. [96] demonstrated that particular study. Heparin can be indirectly angiogenic by 1-10 mg IGF-I given 1 h before coronary occlusion was inducing the liberation of growth factors from the extracelassociated with decreased necrosis as evidenced by lular matrix [101] , preventing the inactivation of growth creatine kinase loss and neutrophil accumulation in the factors [102] and increasing half-life [103] , and by potenischemic area. IGF-I also decreased the incidence of tiating the mitogenic activity of growth factors [104] . myocyte apoptosis in this model [96] .
In two studies [22, 81] , the statistical results were not Bonferroni corrected, overestimating the level of significance obtained.
Study limitations
In all AMI studies analyzed in this review, coronary 6. Future research directions occlusion was induced in unconscious animals. The presence of anesthesia and, in particular, the surgical preparaOur understanding of the role of angiogenic growth tion of these animals, create many problems that imfactors on AMI is still in its infancy. More studies are portantly confound the interpretation of the studies [97] .
needed to further clarify the role FGFs and IGFs on Anesthetics may have major effects on arterial and venous myocardial protection, remodeling, healing, and angiotone, determinants of LV loading conditions. The effects of genesis. Study of the potential roles of additional growth anesthetics on BP, heart rate and contractility have imfactors such as VEGF, TGFs, angiogenin, and HGF in the portant effects on myocardial oxygen demand. Anesthetics AMI setting is also warranted. and invasive surgery have profound effects on autonomic tone, which impacts on many determinants of infarct size.
Some of the reviewed studies did not report infarct size as a percentage of the risk region [20, 22, 23, 79, 89] . The 7. Conclusions major determinants of infarct size are risk region size, followed by myocardial perfusion to the ischemic region,
In conclusion, published data suggest that FGFs and and rate-pressure product [97] . Risk region is a critical IGFs may modestly reduce infarct size after AMI. It is baseline characteristic that is dependent on anatomical unclear whether these effects are due to direct support of considerations. Therefore, the baseline assessment of risk angiogenesis, myocyte protection, salutary hemodynamic region size, as well as the presentation of the infarct size as changes, or effects on apoptosis. The studies are generally a percentage of the risk region, is fundamentally important limited in size, and in many cases technical factors for accurate comparisons of the efficacy of agents for obfuscate appropriate interpretation of the results. The infarct size reduction [97] .
effects of various growth factors in AMI should not be Measurement of risk region with vital dyes several days generalized across agents, and the effects of a specific after coronary occlusion can be associated with a signifiagent in the setting of AMI may differ significantly from cant error [86] . Because collateral development occurs its effect in occlusion / reperfusion. Additional studies in naturally after coronary occlusion, it is likely that substanthis field are warranted.
